Balaglitazone meets diabetes endpoint

Dr. %27 Laboratories Ltd. (NYSE:RDY) and partner Nordic Bioscience A/S (Herlev, Denmark) reported top-line data showing that oral balaglitazone met the primary endpoint of a significantly greater redu...